New viral vectors for Morquio syndrome type A gene therapy

Almeciga, Carlos; Cuaspa, Rocio; Herrera, Juliana; Barbosa, Hector; Barrera, Luis Alejandro

doi:10.1016/j.ymgme.2012.11.022

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contributions from Colombia in basic and applied research for MPS IVA have included production and characterization of recombinant GALNS in bacteria [110,111,112,113,114] and yeast [115,116], the design of viral vectors for gene therapy [117,118,119,120,121,122,123,124], the identification of pharmacological chaperones [125], and the generation of induced pluripotent stem cell lines [126]. Results from recombinant GALNS showed that N-glycosylations are not necessary for production of active enzyme but for cell uptake [112], and that recombinant GALNS produced in the yeast P. pastoris is taken up by cultured cells and reach the lysosomes, in which it can mediate the reduction of KS level [116].…”

Section: Mucopolysaccharidosis Type Iva (Morquio a Syndrome)mentioning

confidence: 99%

A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia

Puentes-Tellez

Lerma-Barbosa

Garzón-Jaramillo

et al. 2020

Heliyon

View full text Add to dashboard Cite

Lysosomal storage diseases (LSDs) are a group of about 50 inborn errors of metabolism characterized by the lysosomal accumulation of partially or non-degraded molecules due to mutations in proteins involved in the degradation of macromolecules, transport, lysosomal biogenesis or modulators of lysosomal environment. Significant advances have been achieved in the diagnosis, management, and treatment of LSDs patients. In terms of approved therapies, these include enzyme replacement therapy (ERT), substrate reduction therapy, hematopoietic stem cell transplantation, and pharmacological chaperone therapy. In this review, we summarize the Colombian experience in LSDs thorough the evidence published. We identified 113 articles published between 1995 and 2019 that included Colombian researchers or physicians, and which were mainly focused in Mucopolysaccharidoses, Pompe disease, Gaucher disease, Fabry disease, and Tay-Sachs and Sandhoff diseases. Most of these articles focused on basic research, clinical cases, and mutation reports. Noteworthy, implementation of the enzyme assay in dried blood samples, led to a 5-fold increase in the identification of LSD patients, suggesting that these disorders still remain undiagnosed in the country. We consider that the information presented in this review will contribute to the knowledge of a broad spectrum of LSDs in Colombia and will also contribute to the development of public policies and the identification of research opportunities.

show abstract

Section: Mucopolysaccharidosis Type Iva (Morquio a Syndrome)mentioning

confidence: 99%

A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia

Puentes-Tellez

Lerma-Barbosa

Garzón-Jaramillo

et al. 2020

Heliyon

View full text Add to dashboard Cite

show abstract

“…En Colombia se cuentan con pocos datos sobre la incidencia de esta enfermedad, aunque recientemente se reportó una incidencia de 1.98:100.000 n.v 34 . Adicionalmente, en Colombia se han adelantado un número importante de investigaciones en diferentes temas relacionados con este grupo de enfermedades tales como: análisis del impacto socio-cultural de la enfermedad 34,62,63 , la identificación de casos de MPS 62,63 , identificación de mutaciones 64 , modelamiento de proteínas defectuosas 65 , producción de enzimas recombinantes 66,67 , y terapia génica [68][69][70] .…”

Section: Mucopolisacaridosisunclassified

Predicción de biomarcadores en mucopolisacaridosis empleando una red metabólica humana

Barreto¹

View full text Add to dashboard Cite

Las mucopolisacaridosis (MPS) son enfermedades de depósito lisosomal, caracterizadas por la deficiencia en las enzimas lisosomales encargadas de la degradación de los glucosaminoglicanos (GAG), esto lleva a su acumulación y al inicio de una serie de procesos patológicos característicos de esta enfermedad. La detección e inicio de tratamiento temprano, son importantes para evitar el deterioro en la calidad de vida del paciente. La medición de GAG en biofluidos es el biomarcador universal en estas patologías, sin embargo, el procesamiento y análisis de los resultados de laboratorio pueden llegar a ser de difícil interpretación y varían según cada paciente, por lo que contar con nuevos biomarcadores tendría un impacto en el diagnóstico y seguimiento de estas enfermedades, con lo cual se podría garantizar un mecanismo de aseguramiento en salud adecuado para estas enfermedades.

show abstract

Evaluation of HIV–1 derived lentiviral vectors as transductors of Mucopolysaccharidosis type IV a fibroblasts

Puentes-Tellez

Sánchez

Rojas-Rodríguez

et al. 2021

Gene

View full text Add to dashboard Cite

New viral vectors for Morquio syndrome type A gene therapy

Cited by 6 publications

References 0 publications

A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia

A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia

Predicción de biomarcadores en mucopolisacaridosis empleando una red metabólica humana

Evaluation of HIV–1 derived lentiviral vectors as transductors of Mucopolysaccharidosis type IV a fibroblasts

Contact Info

Product

Resources

About